Low-molecular weight iron dextran and iron sucrose have similar comparative safety profiles in chronic kidney disease.

M Auerbach, K Al Talib

Journal: Kidney international 2008;73(5):528-30

PMID: 18274543

Free Full Text on Elsevier Science View on PubMed

Abstract

Serious adverse events that occur with the administration of iron dextran are due to the high molecular weight preparations. Conclusions that iron sucrose and ferric gluconate are safer than iron dextran may be premature. Published literature comparing safety profiles of available parenteral iron products is reviewed. Administration of iron salts to pre-dialysis patients with chronic kidney disease may not be optimal. We recommend the total dose infusion of low molecular weight iron dextran as an option for iron replacement.

Address: Auerbach Hematology and Oncology, Baltimore, Maryland 21237, USA. [email protected]

DOI: 10.1038/sj.ki.5002779

Link outs

Free resources

Full Text Sources:

https://linkinghub.elsevier.com/retrieve/pii/S0085...

Medical:

https://medlineplus.gov/kidneydiseases.html

Other Literature Sources:

https://www.lens.org/lens/search/patent/list?q=ref...

MeSH Terms: Chronic Disease, Ferric Compounds, Ferric Oxide, Saccharated, Glucaric Acid, Hematinics, Humans, Infusions, Parenteral, Iron-Dextran Complex, Kidney Diseases